Citations

Clear

116 citation(s) found for "Teng, Li".

Evidence-Based Clinical Practice Guidelines for Laser-Assisted Drug Delivery
Labadie, Jessica G. , Worley, Brandon , Kang, Bianca Y. , Rakita, Uros , Rigali, Sarah , Arndt, Kenneth A., Brauer, Jeremy A., Chandra, Sunandana , Didwania, Aashish , DiGiorgio, Catherine M., Donelan, Mattias, Dover, Jeffrey S. , Geronemus, Roy G. , Goldman, Mitchel P. , Hruza, George J. , Ibrahimi, Omar A. , Kauvar, Arielle N.B. , Kelly, Kristen M. , Krakowski, Andrew C. , Miest, Rachel Y. , Orringer, Jeffrey S. , Ozog, David , Ross, E. Victor , Shumaker, Peter R. , Sobanko, Joseph F. , Suozzi, Kathleen C. , Taylor, Mark B., Teng, Joyce , Uebelhoer, Nathan S., Waibel, Jill , Wanner, Molly, Ratchev, Ina, Poon, Emily , Miller, Corinne H. , Alam, Murad , Miest, Rachel, Kelly, Kristen M , Ibrahim, Sarah A. , Bernstein, Eric F. , Galadari, Hassan , Hædersdal, Merete , Christensen, Rachel E. , Alam, Murad

Mayo Clinic

JAMA Dermatology | August 17, 2022 | Volume: 158 | Issue: 10 | Pages: 1193

10.1001/jamadermatol.2022.3234 | PMID 35976634 Get It

Importance Laser-assisted drug delivery (LADD) is used for various medical and cosmetic applications. However, there is insufficient evidence-based guidance to assist clinicians performing LADD. Objective To develop recommendations for the safe and effective use of LADD. Evidence Review A systematic literature review of Cochrane Central Register of Controlled Trials, Embase, and MEDLINE was conducted in December 2019 to identify publications reporting research on LADD. A multidisciplinary panel was convened to draft recommendations informed by the systematic review; they were refined through 2 rounds of Delphi survey, 2 consensus meetings, and iterative review by all panelists until unanimous consensus was achieved. Findings Of the 48 published studies of ablative fractional LADD that met inclusion criteria, 4 were cosmetic studies; 21, oncologic; and 23, medical (not cosmetic/oncologic), and 6 publications of nonablative fractional LADD were included at the request of the expert panel, producing a total of 54 studies. Thirty-four studies (63.0%) were deemed to have low risk of bias, 17 studies (31.5%) had moderate risk, and 3 (5.5%) had serious risk. The key findings that informed the guidelines developed by the expert panel were as follows: LADD is safe in adults and adolescents (≥12 years) with all Fitzpatrick skin types and in patients with immunosuppression; it is an effective treatment for actinic keratosis, cutaneous squamous cell carcinoma in situ, actinic cheilitis, hypertrophic scars, and keloids; it is useful for epidermal and dermal analgesia; drug delivery may be increased through the application of heat, pressure, or occlusion, or by using an aqueous drug solution; laser settings should be selected to ensure that channel diameter is greater than the delivered molecule; antibiotic prophylaxis is not recommended, except with impaired wound healing; antiviral prophylaxis is recommended when treating the face and genitalia; and antifungal prophylaxis is not recommended. The guideline’s 15 recommendations address 5 areas of LADD use: (I) indications and contraindications; (II) parameters to report; (III) optimization of drug delivery; (IV) safety considerations; and (V) prophylaxis for bacterial, viral, and fungal infections. Conclusions and Relevance This systematic review and Delphi consensus approach culminated in an evidence-based clinical practice guideline for safe and effective use of LADD in a variety of applications. Future research will further improve our understanding of this novel treatment technique.
Dietary Supplements for Pain Relief in Patients with Fibromyalgia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Lim, Kia Teng , Lim, Kia Hui , Zhou, Xuan , Yang, Juan , Shin, Kyung-Min , Mohabbat, Arya B. , Baude, Wyatt W., Nanda, S. , Bauer, David A, Theberath, Monique, Theberath, Nicole, Bauer, Brent A. , Ganesh, Ravindra

Mayo Clinic

The American Journal of Chinese Medicine | June 1, 2022 | Volume: 50 | Issue: 05 | Pages: 1197-1218

10.1142/s0192415x22500495 | PMID 35642461 Get It

Pain is the most frequently encountered symptom by patients with fibromyalgia (FM). Dietary supplements (DSs) in particular have a proven impact as a possible adjunctive therapy for symptom management in FM. However, there is currently no conclusive review outlining the evidence for DSs in pain management in FM. This study aims to assess currently available studies evaluating the use of DSs for pain relief in FM. Randomized controlled trials regarding the use of DSs on adult FM patients were included for evidence synthesis. Study results indicated that DSs significantly relieved pain in FM (SMD 1.23; 95% CI 0.02–2.43, P = 0.046) but did not improve quality of life (QoL) (SMD 0.73; 95% CI −0.07–1.53, P = 0.075) in the data. Adverse events of DSs varied from mild to severe, with the most common being gastrointestinal symptoms and androgenic side effects in 5.7% and 3.9% of patients, respectively. More well-designed RCTs are required in the future. The protocol for this review has been published on PROSPERO (CRD42020149941).
0715 Diagnosis of Sleep Disordered Breathing in Patients with Interstitial Lung Disease: A Retrospective Evaluation of Polysomnogram and Home Sleep Apnea Testing Using Peripheral Arterial Tonometry
Kelly, Bryan T. , Moua, Teng , Escalante, Patricio , Kelly, Bryan

Mayo Clinic

Sleep | May 31, 2022 | Volume: 45 | Issue: Supplement_1 | Pages: A313-A313

10.1093/sleep/zsac079.711 Get It

Abstract Introduction Previous studies have shown that sleep disordered breathing (SDB) is common in patients with Interstitial Lung Disease (ILD), and oximetry is often used for screening prior to further diagnostic testing. Current guidelines recommend polysomnography (PSG) for diagnosis of SDB in patients with significant pulmonary disease, however, home sleep apnea tests (HSAT) are increasingly used in clinical practice for a variety of reasons despite lack of evidence regarding accuracy in this population. In this study, we evaluate the correlation between screening oximetry, a commercial brand HSAT (WatchPAT®) and PSG to examine the diagnostic accuracy of this HSAT technology in patients with ILD. Methods The institution electronic medical record was screened for patients with a diagnosis code for ILD who underwent screening oximetry followed by PSG or HSAT using peripheral arterial tonometry from July 1, 2012 to present. Clinical review confirmed presence of ILD according to American Thoracic Society guidelines. Among the respective cohorts, Paired Wilcoxon Test was used to compare the oximetry 4% oxygen desaturation index (ODI) to the HSAT ODI and PSG apnea-hypopnea index (AHI) as well as percent time spent below oxyhemoglobin saturation of 89%. Spearman correlation was used to correlate the oximetry ODI and parameters of SDB on HSAT and PSG. Results Data was analyzed for 25 patients who had undergone oximetry/HSAT and for 25 patients who had undergone oximetry/PSG. Oximetry ODI showed no significant difference from PSG AHI (p = 0.2635) or between HSAT ODI (p = 0.0755), and no difference was seen in hypoxic time between oximetry and PSG (p = 0.9789). Hypoxic time on HSAT was significantly longer than that on oximetry (p < 0.001). Using HSAT ODI as the standard, HSAT AHI and respiratory disturbance index (RDI) showed rs of 0.9638 and 0.8913 respectively, while oximetry ODI was 0.3893. Compared to PSG AHI, the PSG RDI and oximetry ODI rs were 0.9759 and 0.7407 respectively. Conclusion Among patients with ILD, screening oximetry appears to correlate more strongly with indices of SDB and hypoxic time on PSG rather than HSAT. Further studies are warranted to evaluate efficacy of additional HSAT testing modalities in this patient population. Support (If Any)
Efficacy and Safety of Nintedanib in Elderly Patients with Progressive Fibrosing Interstitial Lung Diseases (ILDs)
Moua, Teng , Wuyts, W.A., Miede, Corinna, Lievens, D., investigators, on behalf of the INBUILD trial, Bonella, Francesco , Okamoto, Masaki , Tomassetti, Sara , Valenzuela, Claudia , Bendstrup, Elisabeth

Mayo Clinic

B22. EMERGING MANAGEMENT OF FIBROTIC ILDs | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A2426-A2426

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2426 Get It

Phenotypic Characteristics of Fibrotic Hypersensitivity Pneumonitis by Machine Learning Consensus Clustering
Moua, Teng , Petnak, Tananchai , Cheungpasitporn, Wisit , Thongprayoon, Charat

Mayo Clinic

C103. IT'S NOT JUST ABOUT IPF | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A4888-A4888

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a4888 Get It

Late Complications of COVID-19
Roden, Anja C. , Johnson, Tucker F. , Aubry, Marie Christine, Butt, Yasmeen M. , Maleszewski, Joseph J. , Larsen, Brandon T. , Tazelaar, Henry D. , Khoór, András , Moua, Teng , Jenkins, Sarah M. , Moyer, Ann M. , Yi, Eunhee , Bois, Melanie C. , Boland, Jennifer M. , Lo, Ying‐Chun , Tazelaar, Henry D. , Smith, Maxwell L. , Yi, Eunhee S.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | March 23, 2022 | Volume: 146 | Issue: 7 | Pages: 791-804

10.5858/arpa.2021-0519-sa | PMID 35319744 Get It

Context.— Studies of lungs in patients with COVID-19 have focused on early findings. Objective.— To systematically study histopathologic and imaging features and presence of SARS-CoV-2 RNA in lung tissue from patients in later stages of COVID-19. Design.— Autopsies, explants, surgical lung biopsies, transbronchial biopsies, cryobiopsies, and needle biopsies from patients with COVID-19 whose onset of symptoms/confirmed diagnosis was more than 28 days before the procedure were studied. Available images were reviewed. Reverse transcription droplet digital polymerase chain reaction for SARS-CoV-2 RNA was performed on lung tissue. Results.— Of 44 specimens (43 patients; median age, 59.3 years; 26 [60.5%] male) features of acute lung injury (ALI) were seen in 39 (88.6%), predominantly organizing pneumonia and diffuse alveolar damage, up to 298 days after onset of COVID-19. Fibrotic changes were found in 33 specimens (75%), most commonly fibrotic diffuse alveolar damage (n = 22) and cicatricial organizing pneumonia (n = 12). Time between acquiring COVID-19 and specimen was shorter in patients with diffuse ALI (median, 61.5 days) compared with patients with focal (140 days) or no ALI (130 days) (P = .009). Sixteen (of 20; 80%) SARS-CoV-2 reverse transcription droplet digital polymerase chain reaction tests were positive, up to 174 days after COVID-19 onset. Time between COVID-19 onset and most recent computed tomography in patients with consolidation on imaging was shorter (median, 43.0 days) versus in patients without consolidation (87.5 days; P = .02). Reticulations were associated with longer time to computed tomography after COVID-19 onset (median, 82 versus 23.5 days; P = .006). Conclusions.— ALI and SARS-CoV-2 RNA can be detected in patients with COVID-19 for many months. ALI may evolve into fibrotic interstitial lung disease.
Challenges in the Diagnosis and Management of Fibrotic Hypersensitivity Pneumonitis: A Practical Review of Current Approaches
Moua, Teng , Petnak, Tananchai , Charokopos, Antonios , Baqir, Misbah , Ryu, Jay H. , Petnak, Tananchai , Ryu, Jay H

Mayo Clinic

Journal of Clinical Medicine | March 8, 2022 | Volume: 11 | Issue: 6 | Pages: 1473

10.3390/jcm11061473 | PMID 35329800 Get It

Recent advances in fibrotic hypersensitivity pneumonitis include improved diagnostic guidance, systematic assessments of immunosuppressive therapy, and the recent availability of antifibrotic therapy (nintedanib) for those with progressive disease. A standardized approach to diagnosis may lead to better inclusion criteria for future therapeutic protocols and delineation of disease or treatment response predictors for real-world management. This review will highlight current diagnostic and treatment challenges and remaining knowledge gaps or areas of uncertainty, with a practical overview of supporting evidence and its clinical implications. Exposure history, serologic testing for antigen sensitivity, bronchoalveolar lavage lymphocytosis, histopathology, and radiologic findings will be covered in the diagnosis section, with immunosuppression, antifibrotic therapy, lung transplantation, and disease prognosis in the treatment and management section.
Three-Dimensional Tendon Scaffold Loaded with TGF-β1 Gene Silencing Plasmid Prevents Tendon Adhesion and Promotes Tendon Repair
Wu, Genbin, Sun, Binbin , Zhao, Chunfeng , Wang, Zhuoying , Teng, Songsong, Yang, Mengkai, Cui, Zhi , Zhu, Guoliang , Yu, Yinxian

Mayo Clinic

ACS Biomaterials Science & Engineering | November 1, 2021 | Volume: 7 | Issue: 12 | Pages: 5739-5748

10.1021/acsbiomaterials.1c00747 | PMID 34723484 Get It

Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray
Camerini, David , Randall, Arlo, Trappl-Kimmons, Krista, Oberai, Amit , Hung, Christopher, Edgar, Joshua , Shandling, Adam D., Huynh, Vu, Teng, Andy , Hermanson, Gary, Pablo, Jozelyn , Stumpf, Megan M. , Lester, Sandra , Harcourt, Jennifer L. , Tamin, Azaibi , Thornburg, Natalie J. , Satheshkumar, Panayampalli S. , Liang, Xiaowu, Kennedy, Richard B. , Yee, Angela , Townsend, Michael B. , Campo, Joseph J. , Kennedy, Richard , Rasheed, Mohammed

Mayo Clinic

Microbiology Spectrum | October 27, 2021 | Volume: 9 | Issue: 2 | Pages: No page available

10.1128/spectrum.01416-21 | PMID 34704808 Get It

With novel mutant SARS-CoV-2 variants of concern on the rise, knowledge of immune specificities against SARS-CoV-2 proteins is increasingly important for understanding the impact of structural changes in antibody-reactive protein epitopes on naturally acquired and vaccine-induced immunity, as well as broader topics of cross-reactivity and viral evolution. A multi-coronavirus protein microarray used to map the binding of COVID-19 patient antibodies to SARS-CoV-2 proteins and protein fragments as well as to the proteins of four other coronaviruses that infect humans has shown specific regions of SARS-CoV-2 proteins that are highly reactive with patient antibodies and revealed cross-reactivity of these antibodies with other human coronaviruses.
Accuracy of a Rapid Multiplex Polymerase Chain Reaction Plus a Chromogenic Phenotypic Test Algorithm for Detection of Extended-Spectrum β-Lactamase and Carbapenemase-Producing Gram-Negative Bacilli in Positive Blood Culture Bottles
Ong, Sean Wei Xiang , Hon, Pei Yun, Wee, Sharon , Chia, Jonathan W. Z., Mendis, Shehara M, Izharuddin, Ezlyn, Lin, Ray Junhao, Chia, Po Ying , Sim, Rees Chin Swee, Chen, Mark , Lye, David Chien , Teng, Christine B. , Tambyah, Paul Anantharajah , Banerjee, Ritu , Patel, Robin , De, Partha Pratim, Chen, Mark I-Cheng , Chow, Angela , Patel, Robin , Kline, Susan , Yoong, Joanne , Vasoo, Shawn

Mayo Clinic

Clinical Infectious Diseases | September 21, 2021 | Volume: 74 | Issue: 10 | Pages: 1850-1854

10.1093/cid/ciab848 | PMID 34554228 Get It

Abstract We studied the performance of an algorithm combining multiplex polymerase chain reaction with phenotypic detection of extended-spectrum β-lactamases and carbapenemases directly from positive blood culture bottles in patients with gram-negative bacteremia and found good concordance with routine cultures. Such an algorithm may be a tool to improve time to optimal therapy in patients with gram-negative bacteremia.